Department of Mechanical Engineering and Material Science, Washington University in St. Louis, Saint Louis, MO 63130, USA.
Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA.
J Control Release. 2018 Sep 28;286:145-153. doi: 10.1016/j.jconrel.2018.07.020. Epub 2018 Jul 26.
Focused ultrasound combined with microbubble-mediated intranasal delivery (FUSIN) is a new brain drug delivery technique. FUSIN utilizes the nasal route for direct nose-to-brain drug administration, thereby bypassing the blood-brain barrier (BBB) and minimizing systemic exposure. It also uses FUS-induced microbubble cavitation to enhance transport of intranasally (IN) administered agents to the FUS-targeted brain location. Previous studies have provided proof-of-concept data showing the feasibility of FUSIN to deliver dextran and the brain-derived neurotrophic factor to the caudate putamen of mouse brains. The objective of this study was to evaluate the biodistribution of IN administered gold nanoclusters (AuNCs) and assess the feasibility and short-term safety of FUSIN for the delivery of AuNCs to the brainstem. Three experiments were performed. First, the whole-body biodistribution of IN administered Cu-alloyed AuNCs (Cu-AuNCs) was assessed using in vivo positron emission tomography/computed tomography (PET/CT) and verified with ex vivo gamma counting. Control mice were intravenously (IV) injected with the Cu-AuNCs. Second, Cu-AuNCs and Texas red-labeled AuNCs (TR-AuNCs) were used separately to evaluate FUSIN delivery outcome in the brain. Cu-AuNCs or TR-AuNCs were administered to mice through the nasal route, followed by FUS sonication at the brainstem in the presence of systemically injected microbubbles. The spatial distribution of Cu-AuNCs and TR-AuNCs were examined by autoradiography and fluorescence microscopy of ex vivo brain slices, respectively. Third, histological analysis was performed to evaluate any potential histological damage to the nose and brain after FUSIN treatment. The experimental results revealed that IN administration induced significantly lower Cu-AuNCs accumulation in the blood, lungs, liver, spleen, kidney, and heart compared with IV injection. FUSIN enhanced the delivery of Cu-AuNCs and TR-AuNCs at the FUS-targeted brain region compared with IN delivery alone. No histological-level tissue damage was detected in the nose, trigeminal nerve, and brain. These results suggest that FUSIN is a promising technique for noninvasive, spatially targeted, and safe delivery of nanoparticles to the brain with minimal systemic exposure.
聚焦超声联合微泡介导的经鼻给药(FUSIN)是一种新的脑部药物输送技术。FUSIN 利用鼻腔途径进行直接的鼻脑药物给药,从而绕过血脑屏障(BBB)并最大程度减少全身暴露。它还利用 FUS 诱导的微泡空化来增强经鼻(IN)给予的药物向 FUS 靶向脑区的输送。先前的研究提供了概念验证数据,表明 FUSIN 向小鼠大脑尾状核输送葡聚糖和脑源性神经营养因子是可行的。本研究的目的是评估 IN 给予的金纳米团簇(AuNCs)的全身分布,并评估 FUSIN 用于将 AuNCs 递送到脑干的可行性和短期安全性。进行了三项实验。首先,使用体内正电子发射断层扫描/计算机断层扫描(PET/CT)评估 IN 给予的铜合金 AuNCs(Cu-AuNCs)的全身分布,并通过离体伽马计数进行验证。对照小鼠静脉(IV)注射 Cu-AuNCs。其次,分别使用 Cu-AuNCs 和 Texas 红标记的 AuNCs(TR-AuNCs)来评估 FUSIN 在大脑中的递送效果。Cu-AuNCs 或 TR-AuNCs 通过鼻腔途径给予小鼠,然后在系统给予的微泡存在下对脑干进行 FUS 声处理。通过离体脑切片的放射自显影和荧光显微镜分别检查 Cu-AuNCs 和 TR-AuNCs 的空间分布。第三,进行组织学分析以评估 FUSIN 治疗后鼻子和大脑是否存在任何潜在的组织损伤。实验结果表明,与 IV 注射相比,IN 给药导致血液、肺、肝、脾、肾和心脏中 Cu-AuNCs 的积累显著降低。与单独 IN 给药相比,FUSIN 增强了 FUS 靶向脑区的 Cu-AuNCs 和 TR-AuNCs 的递送。在鼻子、三叉神经和大脑中均未检测到组织学水平的组织损伤。这些结果表明,FUSIN 是一种有前途的技术,可用于将纳米颗粒非侵入性、空间靶向和安全地递送到大脑,同时最大限度地减少全身暴露。